NCT07780357Not yet recruiting
HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
Development and Application of an HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
The investigators propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis/cirrhosis patients, using multimodal data encompassing longitudinal clinical data, serum glycomics profiles, and liver biopsy histopathological images.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 19 Aug 2026
- Start date
- 20 Aug 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Beijing Friendship Hospital
- NCT number
- NCT07780357
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 20 Aug 2026 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosis of Hepatocellular carcinoma (HCC) or liver transplantation at baseline or within 6 months after baseline/enrollment.
Other illness
- Coexisting other chronic liver diseases, such as genetic/metabolic liver diseases, drug-induced liver injury, or severe steatotic liver disease.
- Coexisting other malignancies (except those considered cured).
Who the study is looking for
- Aged ≥18 years, both sexes eligible.
- Diagnosed with hepatitis B-related liver fibrosis or cirrhosis based on clinical assessment or liver histopathology.
- Undergoing antiviral treatment.
- Follow-up duration between 0.5- 5 years.
- Availability of baseline data and at least two longitudinal follow-up visits.
- Clinical outcomes during the follow-up period are traceable.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Friendship Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.